It is no longer the current profile. Read the canonical profile and its correction notice.
What this version reported
The label describes small open-label and randomized studies and states that fracture reduction has not been demonstrated. It warns of a possible increase in cancer risk.↗
Reader guide in this version
Key takeaway
Calcitonin salmon is a synthetic version of the hormone calcitonin found in salmon, and the active ingredient in Miacalcin.1,2 Its U.S. label covers symptomatic Paget’s disease of bone and postmenopausal osteoporosis when other treatments are not suitable, and high blood calcium. The label states that it has not been shown to reduce fractures.1 The label warns that a meta-analysis of 21 clinical trials suggests a higher risk of cancer in people treated with calcitonin salmon, and says the need for continued use should be re-evaluated periodically.1
At a glance
- What it is
- A calcitonin receptor agonist that acts mainly on bone. The label states that salmon calcitonin acts like mammalian calcitonins but is more potent and longer-lasting.1
- FDA status
- FDA-approved. Drugs@FDA lists Miacalcin under NDA 017808 with an original approval date of July 3, 1986. The cited label has no boxed warning.1,2
- Human evidence
- Small open-label and randomized studies from its original approvals, described in the label, which states there is no evidence it lowers the risk of osteoporotic fracture.1
- Evidence strength
- Smaller controlled human trials
What is calcitonin salmon?
Calcitonin salmon is a lab-made form of the calcitonin hormone of salmon. Calcitonin is a peptide hormone that slows the breakdown of bone.1
In the United States it is the active ingredient of Miacalcin, approved under NDA 017808, according to Drugs@FDA. The label gives 1975 as the year calcitonin salmon was first approved in the United States.1,2
How does calcitonin salmon work?
The label states that calcitonin salmon is a calcitonin receptor agonist that acts primarily on bone, with direct effects on the kidney and digestive tract also recognized.1
The label also states that calcitonin’s role in normal human bone physiology is still not completely understood, although calcitonin receptors are found on the cells that break down and build bone.1
What do human studies show?
In open-label Paget’s disease trials of several months to two years with historical controls, blood and urine markers of bone turnover improved by more than 30% in about two-thirds of patients, and bone pain improved in a similar share, according to the label.1
In two randomized, open-label osteoporosis studies, total body calcium rose at one year and then trended down. New spinal fractures were similar: 6 with calcitonin salmon and 5 in the control group in year one, and 7 in each in year two.1
The label states that no evidence currently shows it decreases the risk of osteoporotic fracture, and that a controlled study stopped early failed to show any benefit on fracture rate.1
What the evidence base contains
- Controlled human trial Two randomized, open-label, two-year studies in postmenopausal women with low bone mass (69 women combined), with total body calcium as the main outcome, described in the label.1
- Small, short, or incompletely reported human study Open-label trials in Paget’s disease using historical controls, and four open-label trials in 53 patients with high blood calcium, described in the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is calcitonin salmon FDA-approved?
Yes. Drugs@FDA lists Miacalcin, application NDA 017808, with an original approval date of July 3, 1986.2
The Miacalcin label cited here (DailyMed SPL version 9, published June 19, 2026) states that it is indicated for symptomatic Paget’s disease of bone and postmenopausal osteoporosis when alternative treatments are not suitable, and for high blood calcium.1
The label has no boxed warning. Its warnings include serious allergic reactions including fatal anaphylaxis, low blood calcium, a possible increase in cancer risk, and antibodies that may cause a loss of response.1
What is still unknown?
Whether it prevents fractures: the label states that fracture reduction has not been demonstrated.1
Its effect on spinal bone density beyond one year, which the label states no adequate controlled trial has examined.1
Sources for this version
- 1MIACALCIN (calcitonin salmon) injection, solution · SPL version 9 · published 2026-06-19 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA: MIACALCIN (calcitonin salmon), NDA 017808 · original approval July 3, 1986 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026